Next Article in Journal
The “Magnesium Sacrifice” Strategy Enables PMMA Bone Cement Partial Biodegradability and Osseointegration Potential
Next Article in Special Issue
Serum and Hepatic Autofluorescence as a Real-Time Diagnostic Tool for Early Cholestasis Assessment
Previous Article in Journal
AMP-Activated Protein Kinase as a Reprogramming Strategy for Hypertension and Kidney Disease of Developmental Origin
Previous Article in Special Issue
Microsatellite Instability Occurs Rarely in Patients with Cholangiocarcinoma: A Retrospective Study from a German Tertiary Care Hospital
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 19
Issue 6
10.3390/ijms19061745
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Peribiliary Glands as the Cellular Origin of Biliary Tract Cancer

by
Hayato Nakagawa
*,
Yuki Hayata
,
Tomoharu Yamada
,
Satoshi Kawamura
,
Nobumi Suzuki
and
Kazuhiko Koike
Department of Gastroenterology, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(6), 1745; https://doi.org/10.3390/ijms19061745
Submission received: 24 May 2018 / Revised: 8 June 2018 / Accepted: 10 June 2018 / Published: 12 June 2018
(This article belongs to the Special Issue Molecular and Cellular Interactions in Biliary Tree Development, Diseases and Cancer)
Browse Figures
Versions Notes

Abstract

:
The identification of the cellular origin of cancer is important for our understanding of the mechanisms regulating carcinogenesis, thus the cellular origin of cholangiocarcinoma (CCA) is a current topic of interest. Although CCA has been considered to originate from biliary epithelial cells, recent studies have suggested that multiple cell types can develop into CCA. With regard to the hilar and extrahepatic bile ducts, peribiliary glands (PBGs), a potential stem cell niche of biliary epithelial cells, have attracted attention as the cellular origin of biliary tract cancer. Recent histopathological and experimental studies have suggested that some kinds of inflammation-induced CCA and intraductal papillary neoplasms of the bile duct are more likely to originate from PBGs. During inflammation-mediated cholangiocarcinogenesis, the biliary epithelial injury-induced regenerative response by PBGs is considered a key process. Thus, in this review, we discuss recent advances in our understanding of cholangiocarcinogenesis from the viewpoint of inflammation and the cellular origin of CCA, especially focusing on PBGs.

Graphical Abstract

1. Introduction

Cholangiocarcinoma (CCA) is a highly malignant tumor exhibiting feature of biliary epithelial differentiation. CCA is classified, according to its anatomical location, as intrahepatic CCA (iCCA), perihilar CCA (pCCA), or distal CCA (dCCA). pCCA and dCCA are distinguished by the insertion site of the cystic duct, and iCCA is defined as CCA arising from the second-order bile duct in the liver [1,2]. Further classification of CCA is based on tumor morphology. The iCCAs are classified into mass-forming, periductal-infiltrating, and intraductal growth, and pCCAs/dCCAs are classified into flat- and nodular-infiltrating, and papillary types [3]. Although surgical resection is the sole potentially curative treatment, regardless of anatomical location and morphological subtype, only 20–30% of CCA patients are amenable to surgical resection because CCA is usually diagnosed at an advanced stage. In addition, the efficacies of other treatment options, which include radiation and chemotherapy, are limited, and there is presently no approved molecular-targeted therapy for CCA [4,5]. Therefore, understanding the molecular mechanisms and the unique pathogenic biology of CCA is an imperative issue.
The identification of the cellular origin of cancer is important for our understanding of the mechanisms regulating cancer. Cancer originates from a normal cell that accumulates genetic mutations and undergoes transformation [6]. Many studies using mouse models have identified tissue-resident, long-lived stem cells in various organs and suggested that these cells are the main cellular origin of cancer [7]. A well-characterized example of this concept is intestinal carcinogenesis originating from the intestinal crypt stem cells [8]. However, the location of tissue-resident adult stem cells has not been definitively determined in the biliary tract. Notably, although biliary tract cancer has been considered to originate from biliary epithelial cells (BECs), recent mouse genetic lineage-tracing experiments have suggested that multiple cell types, including mature hepatocytes, can give rise to iCCA [9,10]. Regarding pCCA/dCCA, anatomical and immunohistochemical analyses have revealed that peribiliary glands (PBGs), clusters of epithelial cells residing in the submucosal compartment of extrahepatic and large intrahepatic bile ducts (EHBDs and IHBDs, respectively), are potential stem/progenitor cell niches of BECs; thus, PBGs have attracted attention as a potential origin of pCCA/dCCA [11].
Although a mouse disease model is a powerful tool to investigate the cellular origin of cancer, there has not been a good mouse model for extrahepatic CCA. Recently, we established a new mouse model of extrahepatic CCA whose malignant progression depends on biliary epithelial injury and inflammation. This mouse model has suggested that PBGs are the cellular origin of extrahepatic CCA [12]. Thus, in this review, we first provide a brief overview of CCA, and then discuss recent advances in the understanding of cholangiocarcinogenesis from the viewpoint of the inflammation and cellular origin of CCA, especially focusing on PBGs.

2. Chronic Inflammation Is Key in the Epidemiology and Risk Factors of CCA

The global incidence of CCA varies widely and is highest in Southeast Asia, China, and the Republic of Korea, which is approximately 10-fold higher than that of the United States or Europe [2,13]. Such a wide geographical variation in the incidence of CCA is mostly attributed to the prevalence of risk factors, including liver fluke, hepatitis viral infection, primary sclerosing cholangitis (PSC), hepatolithiasis, and congenital abnormalities of the pancreatic and biliary ducts [1]. Infection with liver flukes, Opisthorchis viverrini and Clonorchis sinesis, is highly prevalent in East Asia, and a meta-analysis revealed its strong association with CCA (odds ratio (OR), 4.8; 95% confidence interval (CI), 2.8–8.4) [14]. Chronic infection with hepatitis B virus (HBV) or hepatitis C virus, which is also common in Asian countries, increases the risk of iCCA (OR, 2.6, 95% CI, 1.5–4.6; OR, 1.8, 95% CI, 1.4–2.4, respectively). PSC is a well-established risk factor, especially in Western countries, with a lifetime risk of CCA estimated as 7–14% [15,16,17,18]. Importantly, most of these conditions create chronic inflammation in the biliary tree and liver, indicating that chronic inflammation plays a key role in cholangiocarcinogenesis.
Although Virchow first suggested the relationship between inflammation and cancer in the 19th century, the molecular mechanisms have been gradually identified during the last 10–20 years [19]. The mechanism of hepatocellular carcinoma (HCC), the other type of liver cancer, is one of the most extensively investigated inflammation-based carcinogenic processes, because more than 90% of HCCs develop in the context of chronic liver damage and inflammation [20]. Chronic liver damage induces a persistent cycle of necroinflammation and hepatocyte regeneration, resulting in genetic mutations in hepatocytes and expansion of initiated cells, eventually leading to HCC. During these processes, several signaling pathways, such as the nuclear factor-κB (NF-κB) and STAT3 pathways, and inflammatory cytokines, such as tumor necrosis factor (TNF)-α and interleukin (IL)-6, play important roles in cellular autonomous and non-autonomous behaviors [21,22,23]. Furthermore, recent studies regarding gastrointestinal tract cancer have reported that chronic epithelial injury accompanied by inflammation induces expansion of stem cell niches, leading to genetic and epigenetic alterations in stem/progenitor cells, eventually resulting in invasive cancer [7]. These findings suggested that chronic epithelial injury and inflammation might accelerate tissue-resident stem/progenitor cell-derived carcinogenesis. Although similar theories have been proposed for inflammation-related cholangiocarcinogenesis, the exact mechanisms and cellular origins in cholangiocarcinogenesis have remained unclear. However, several recent studies have shed some light on this intriguing and unsolved problem, as discussed in later sections.

3. Mutation Spectrum of CCA

Before discussing the mechanisms and cellular origins of CCA, recent advances in CCA genomics should be mentioned. Next-generation sequencing technology has enabled comprehensive mutational and transcriptome profiling of CCA and five identified core driver mutations (TP53, KRAS, SMAD4, ARID1A, and BAP1) and five molecular modules (kinase-RAS, TGFβ-SWI/SNF-MYC, TP53, RB-cell cycle, and epigenetic regulators) [24,25]. Epigenetic regulators include IDH1/2, BAP1, methylcytosine dioxygenase family members (TET1, TET2, and TET3), and histone demethylases and methylases (MLL2 and MLL3). In addition, some molecular alterations characteristics of CCA have been identified, such as fusion transcripts of FGFR2 and the protein kinase A (PKA) pathway (PRKACA or PRKACB) [24,26]. However, the frequency of each genetic alteration is not high and even mutated TP53, the most commonly mutated gene, is present only in approximately 35% of CCA patients, indicating that CCA is a heterogeneous cancer.
IDH1/2 and BAP1 are frequently mutated in liver fluke-related CCA, whereas TP53 mutations show a reciprocal pattern [27]. Furthermore, the frequencies of KRAS and IDH1/2 mutations are significantly low in hepatitis virus-related iCCA when compared with hepatitis virus-unrelated iCCA [28,29]. In contrast, TERT promoter hotspot mutations are strongly associated with hepatitis virus-related iCCA [29]. These findings indicated that underlying etiologies influence the mutational profile of CCA. In addition, anatomical location is also an important determinant for genetic alterations in CCA. FGFR2 fusions and IDH1/2 mutations occur exclusively in iCCA, and BAP1 is frequently mutated in iCCA when compared with extrahepatic CCA and gallbladder cancer. However, fusion of PRKACA or PRKACB and mutations of ELF3 predominantly occur in extrahepatic CCA [24]. These findings suggest that the carcinogenesis process may differ according to the anatomical subtypes and underlying etiologies of CCA. Although the same chemotherapeutic strategy is presently used for CCA, irrespective of these factors, more personalized approaches should be explored. For example, clinical trials of kinase inhibitors targeting FGFR2 are ongoing. The response percentage of a recent phase 2 clinical trial was 18.8% for FGFR2 fusion-positive CCA; however, acquired resistant mutations to FGFR inhibition were identified [30].

4. Cellular Origins of iCAA

The biliary tree is grossly divided into IHBDs and EHBDs, and IHBDs are subdivided into large and small IHBDs [31]. Area ducts, segmental ducts, and right/left hepatic ducts are classified as large IHBDs, while interlobular bile ducts and septal ducts are classified as small IHBDs. The canals of Hering connect the proximal end of small IHBDs to bile canaliculi that are formed by the apical membrane of adjacent hepatocytes. These classifications are important because BECs of EHBDs and large IHBDs differ functionally and morphologically from those of small IHBDs. In addition, in the embryonic stage, EHBDs develop from hepatic endodermal cells in the caudal region of embryonic hepatic diverticula, while IHBDs originate from periportal hepatoblasts, forming ductal plates that originate from the cranial part of hepatic diverticula [32,33,34]. Therefore, small IHBDs, large IHBDs, and EHBDs may exhibit distinct properties and different carcinogenetic processes. Furthermore, based on the anatomical location and developmental processes of the liver, adult liver stem/progenitor cells have been suggested to reside in the canals of Hering [35], so these cells may be a potential origin of liver cancer, including iCCA.
Genetic lineage-tracing studies in mice facilitating the conditional expression of a reporter gene in a targeted cellular population have led to a number of significant advances in our understanding of tissue homeostasis and the cellular origins of cancer [36]. Sekiya and Suzuki investigated the cellular origin of iCCA using a mouse model of thioacetamide (TAA)-induced iCCA in combination with genetic lineage-tracing methods [9]. Rosa26-Lox-Stop-Lox(LSL)-LacZ reporter mice were crossed with AlbuminCreERT mice or K19CreERT mice, in which hepatocytes and BECs (including cells in the canals of Hering) were genetically labeled in a cell type specific manner by tamoxifen (TAM) administration. Surprisingly, iCCAs were derived from hepatocytes rather than from BECs in this model. Chronic liver injury caused by continuous administration of TAA induced conversion of hepatocytes into ductal cells through Notch activation, and eventually led to iCCAs. Another study also suggested the possibility of mature hepatocytes as the cellular origin of iCCA, by introducing hepatocyte specific activation of Akt and Notch pathways by hydrodynamic tail vein injection in combination with genetic lineage-tracing methods [10]. Importantly, because liver injury has been known to induce ductular metaplasia of hepatocytes [37,38,39], chronic liver injury-related iCCAs may be more prone to originate from hepatocytes through ductular metaplasia. Whether iCCAs originate from hepatocytes in humans remains unknown, but there have been some suggestive findings. First, HBV genome integration was detected in HBV-related iCCAs [24,29]. Because HBV shows strong tropism for hepatocytes, these iCCAs may be derived from HBV-infected hepatocytes. Second, mutation profiles in hepatitis-positive iCCAs were similar to those of HCCs, but distinct from hepatitis-negative iCCAs [29], suggesting that chronic hepatitis-related iCCAs and HCCs may arise from the same cellular origins, including mature hepatocytes or liver stem/progenitor cells. Third, intracytoplasmic p62-positive hyaline bodies that are specific for damaged hepatocytes are commonly seen in hepatitis-related iCCAs [40]. Thus, chronic liver injury-mediated ductular metaplasia of hepatocytes may also be involved in human iCCAs.
In contrast, some studies reported that iCCAs originated from BECs. Mice with duct cell specific Kras activations and phosphatase and tensin homologue (PTEN) deletions generated by crossing K19CreERT mice with LSL-KrasG12D and Ptenflox/flox mice developed iCCAs, while mice with hepatocyte specific Kras activations and PTEN deletions generated using AlbuminCreERT mice developed HCCs [41], suggesting that iCCAs and HCCs are derived from BECs and hepatocytes, respectively. In addition, mice with duct cell specific deletion of p53 generated by crossing K19CreERT mice with Tp53flox/flox mice in combination with chronic TAA administration developed iCCAs from BECs [42]. Taken together, both hepatocytes and BECs may be cellular origins of iCCAs in a context-dependent manner (Table 1).

5. PBGs Are Possible Stem/Progenitor Niches for BECs

Next, we review the recent advances in the understanding of stem/progenitor cells and carcinogenesis in large IHBDs and EHBDs. Tubuloalveolar glands with mucinous and serous acini, so-called PBGs, are distributed around large IHBDs and EHBDs. PBGs can be further classified into intramural and extramural glands based on the distance from the bile duct lumen. PBGs are predominantly located at branching points of the biliary tree, such as the hilar bile duct, cystic duct, and periamupullary region, and they connect to the bile duct lumen through small canals [11]. Although PBGs were identified by anatomists in the 19th century, their pathophysiological role has not been definitively identified [31].
Recent studies have suggested the presence of mutipotent adult stem/progenitor cells in human PBGs. Although the majority of cells in PBGs are sero-mucinous epithelial cells and are considered to modulate bile composition by secreting serous and mucinous components, some populations were found to express endodermal stem/progenitor cell markers, such as PDX1, Sox9, and Sox17, which are transcription factors functionally involved in the development of the pancreatico-biliary system [43,44,45]. PBGs also express several other stem/progenitor cell markers (Table 2), and importantly, these markers are also known as cancer stem cell markers [46,47]. Isolated cells from PBGs could clonogenically expand in vitro and differentiate into hepatocytes, cholangiocytes, and pancreatic β-cells, and these cells could be transplanted into the liver of immunocompromised mice and function as differentiated hepatocytes and cholangiocytes [48]. Immunohistochemical analyses showed that cells with stem/progenitor properties appeared to be located at the bottom of PBGs near the fibromuscular layer [47]. A recent anatomical study performing three-dimensional reconstruction of mouse EHBDs showed that PBGs elongate to form and elaborate a peribiliary network with the EHBD wall, and could proliferate in response to biliary epithelial injury such as rhesus rotavirus infection and ligation of the common bile duct [49]. In addition, significant proliferation and hyperplasia of PBGs were observed in patients with various hepatobiliary diseases, such as bacterial cholangitis, PSC, liver fluke infection, hepatolithiasis, and cirrhosis [50,51,52,53]. Furthermore, injury of PBGs was strongly associated with the occurrence of biliary structures following liver transplantation [54]. Notably, cells in PBGs responded to diabetes with proliferation and differentiation toward insulin-producing cells in human and rodents [55]. Based on these findings, biliary tree stem/progenitor cells have been considered to reside in PBGs that may participate in the renewal of surface BECs by supplying mature cholangiocytes from deep to the surface side, as is the case in intestinal crypts [11]. Accordingly, PBGs can also be a potential cellular origin of pCCA/dCCA.

6. A Mouse Model Suggests PBGs Are the Cellular Origin of CCA

Because the lack of an appropriate mouse model has hampered the investigation of extrahepatic CCA, we tried to establish a new mouse model. We first generated mice with TAM-inducible duct cell specific Kras activation and TGFβR2 deletion by crossing LSL-KrasG12D, Tgfbr2flox/flox, and K19CreERT mice (KT-K19CreERT) based on the frequent alterations of Ras and TGFβ/SMAD signaling pathways in human CCA. However, KT-K19CreERT mice only developed mild hyperplasia in the EHBDs. Surprisingly, additional deletion of the adhesion molecule, E-cadherin, by crossing KT-K19CreERT mice with Cdh1flox/flox mice (KTC-K19CreERT), rapidly induced invasive extrahepatic CCA within four weeks of TAM administration [12]. Histologically, moderately to poorly differentiated adenocarcinoma cells expanded along the EHBD wall (so-called periductal infiltration) and extended to the intrahepatic hilar area, including the large IHBDs. In contrast, the peripheral small IHBDs revealed only dysplastic changes, but did not develop peripheral type iCCA, despite a similar gene recombination rate among parts of the biliary tree (approximately 40%). Furthermore, although CCA extended to the cystic duct, the gallbladder was almost intact. Thus, the sensitivity to these mutations differed depending on the location in the biliary tree.
E-cadherin is the core protein connecting the epithelial adherens junctions with neighboring cells, whose loss is associated with poor prognosis in various cancers, including CCA [56,57]. Additionally, there is growing evidence that dysregulation of E-cadherin and its related protein-mediated cell–cell junctions can cause biliary tract diseases in mice. We previously reported that liver specific E-cadherin knockout mice, generated by crossing Cdh1flox/flox mice with Albumin-Cre mice, developed sclerosing cholangitis due to an impaired intrahepatic biliary network, and induced liver tumors with an epithelial–mesenchymal transition (EMT) phenotype when crossed with LSL-KrasG12D mice [58]. Mice with liver specific deletion of α-catenin, β-catenin, or p120 catenin, which form adherens junction complexes with E-cadherin, have also been shown to develop cholestatic liver diseases [59,60,61]. Importantly, E-cadherin expression in human BECs typically exhibits a clear membranous pattern, whereas BECs in patients with PSC have fragmented and cytoplasmic expression patterns of E-cadherin [62]. A recent study showed that lysyl oxidase-like protein 2 (LOXL2) produced by reactive BECs, portal myofibroblasts, and Kupffer cells repressed E-cadherin expression and disrupted the barrier function of BECs through Snail activation, resulting in aggravation of cholestatic liver injury in mice [63]. An inverse correlation between LOXL2 and E-cadherin expression was confirmed in medium-sized bile ducts from PSC patients. These findings indicated the importance of E-cadherin as a guardian to maintain the homeostasis of biliary systems, which is the reason we deleted E-cadherin in KT-K19CreERT mice.
In KTC-K19CreERT mice, E-cadherin deletion led to loss of cell–cell adhesion of BECs in EHBDs, which resulted in detachment of BECs from the EHBD wall (Figure 1A). The epithelial defect caused by E-cadherin deletion subsequently induced inflammation and a regenerative response by PBGs (Figure 1B). However, because PBGs supplied the niche where cells harboring mutations could survive, the regenerative response to biliary injury resulted in promotion of CCA development from PBGs. Time course analyses of EHBD tissue revealed that PBGs gradually became enlarged and morphologically dysplastic, accompanied by mitotic figures during this process (Figure 1A). Genetic lineage tracing experiments by crossing with Rosa26-LSL-LacZ reporter mice (KTC-LacZ-K19CreERT) also suggested PBGs as the cellular origin of CCA (Figure 1C), and indeed, the distribution of CCA in KTC-K19CreERT mice largely corresponded with the distribution of PBGs (i.e., EHBDs and perihilar large IHBDs). In humans, proliferation and hyperplasia of PBGs were observed in patients with various types of biliary diseases as mentioned above [50,51,52,53]. An extensive histological analysis of human livers identified early and pre-invasive lesions of CCAs (biliary intraepithelial neoplasms) in PBGs [64]. PBGs of patients with hepatolithiasis frequently harbor Kras mutations [65], and PBGs in PSC patients express the DNA damage marker γH2AX and EMT markers, such as Snail and α-SMA, accompanied by activation of Sonic Hedgehog (Shh) signaling, as is the case in KTC-K19CreERT mice [51]. Inhibition of Shh signaling was shown to suppress CCA development in experimental models [66]. Thus, KTC-K19CreERT mice mimic the carcinogenesis process of chronic biliary injury-related CCAs in humans, and biliary injury-related CCAs are more likely to originate from PBGs. In addition, CCA arising from PBGs may tend to spread through the PBG network, which leads to periductal infiltration. Consistent with this possibility, a recent detailed histological study identified the periductal spread of pCCA through the PBG network in humans [67].

7. Interleukin (IL)-33 Promotes Proliferation of PBGs and Development of CCAs

Death-driven compensatory proliferation to repair tissue defects promotes inflammation-associated carcinogenesis though production of various tumor-promoting cytokines and chemokines that can stimulate proliferation and survival of premalignant cells [68]. We recently established a method of biliary organoid culture from mouse EHBDs following gene recombination using a lentivirus expressing Cre-recombinase, which can recapitulate loss of E-cadherin-induced shedding of BECs and form subcutaneous tumors in mice (Figure 1D). Using these organoids, we performed transcriptome analyses and identified IL-33 as a key factor linking biliary epithelial injury, regeneration, and cholangiocarcinogenesis [12]. IL-33 is a member of the IL-1 family, originally described as an inducer of type 2 innate immunity in parasitic infections or allergies [69], and it was recently reported to promote BEC proliferation, particularly in EHBDs through activation of type 2 innate lymphoid cells (ILC2s) [70]. Importantly, IL-33 functions as an “alarmin”, released from dying or damaged cells due to infection or tissue injury, and subsequently induces a Th2 immune response to not only eliminate pathogens, but also to repair the injured tissue [69,71]. In KTC-K19CreERT mice, dying or damaged BECs due to loss of E-cadherin release IL-33 as an alarm signal that, in turn, stimulates regeneration by PBGs through secretion of IL-13 and amphiregulin from ILC2, eventually resulting in promotion of cholangiocarcinogenesis from PBGs. Furthermore, exogenous administration of IL-33 to KT-K19CreERT mice induced CCA development, suggesting that IL-33 cooperates with the effects of Kras and TGFβR2 mutation in the development of CCA. Of note, patients with liver fluke infection also showed significantly increased biliary epithelial IL-33 expression and serum IL-33 levels [72]. Together with our data, IL-33 may be a link between liver fluke infection and CCA development. Blocking IL-33 significantly suppressed CCA development in KTC-K19CreERT mice, so IL-33 may be a potential therapeutic target for CCA.
IL-33 may also be implicated in the unique distribution of CCA in KTC-K19CreERT mice, which develop predominantly in EHBDs and perihilar IHBDs. Exogenous administration of IL-33 induced inflammation and BEC proliferation in EHBDs and perihilar large IHBDs, whereas the peripheral small IHBDs and gallbladder were largely unaffected. IL-33-administered KT-K19CreERT mice also showed a similar distribution of CCA. Although IL-33 was shown to have a direct proliferative effect on cholangiocytes in vitro, this effect was restricted in cells derived from EHBDs, but not from small IHBDs [70]. In human CCAs, IL-33 is predominantly expressed in large-duct iCCAs and pCCAs when compared with small-duct iCCAs [73]. These findings suggested that IL-33 might be more dominantly involved in cholangiocarcinogenesis of pCCA/dCCA. Of note, although administration of IL-33 induced proliferation of both luminal surface BECs and PBGs, Ki67 staining revealed that IL-33 exerted greater effects on proliferation of PBGs when compared with surface BECs [12], suggesting that IL-33 may accelerate CCA development from PBGs.
Yamada et al. showed that transposase-mediated transduction of active Akt and YAP in BECs, coupled with bile duct ligation, followed by IL-33 administration, resulted in CCA in mice [74]. In this study, IL-33 enhanced IL-6 expression in cholangiocytes, which in turn activated STAT3 signaling and facilitated the development of CCA. IL-6/STAT3 signaling is an important pathway in inflammation-associated cancers, such as HCC and colorectal cancer [75,76,77]. A gene expression profiling study of human iCCA identified two main subclasses, the inflammation class and the proliferation class, and activation of the IL-6/STAT3 signaling pathway was the main component of the inflammation class [78]. Mouse CCA induced by activation of Akt and YAP in combination with IL-33 exhibited a similar expression pattern of human CCA [74]. Serum IL-6 levels have been reported as potential biomarkers of CCA [79,80], which further supports the significance of this pathway. Therefore, IL-33-mediated IL-6/STAT3 activation may play a key role in inflammation-associated cholangiocarcinogenesis. Proposed mechanisms involving the BEC injury-induced regenerative inflammatory response and cholangiocarcinogenesis from PBGs are shown in Figure 2.
Very recently, the other alarmin high-mobility group B1 (HMGB1) has been reported to play a key role in chronic liver injury-induced ductular/progenitor cell expansion in the liver (so-called ductular reaction) [81,82]. Liver specific knockout of HMGB1 in mice reduced not only the ductular reaction, but also chronic liver injury or autophagy deficiency-associated HCC development. Therefore, alarmins other than IL-33 may also be implicated in BEC injury-induced regenerative inflammatory responses, and cholangiocarcinogenesis from PBGs.

8. PBGs Are the Potential Cellular Origin of Intraductal Papillary Neoplasms of the Biliary Duct

Another type of biliary tumor is biliary cystic neoplasm, which is classified as mucinous cystic neoplasm (MCN) and intraductal papillary neoplasm of the biliary duct (IPNB), according to the 2010 World Health Organization classification [3]. MCN is characterized by mucin-positive lining epithelia associated with ovarian-like stroma in the cyst wall, and occurs almost exclusively in females. MCN usually lacks luminal communication with the bile duct lumen. On the other hand, IPNB shows papillary or villous growth of differentiated neoplastic epithelia and exhibits luminal communication with the bile duct lumen. IPNB is considered to arise from luminal BECs, and affected ducts show cystic dilatation due to mucin-hypersecretion. Based on these findings, IPNB is regarded as a biliary counterpart of intraductal papillary mucinous neoplasms (IPMNs) of the pancreas [83,84]. Although the prognosis of IPNB is better compared with classical CCA, IPNB is also recognized as a precursor of invasive carcinoma.
Recently, several histological studies have suggested not only luminal BECs, but also PBGs as the potential cellular origin of IPNB. Nakanishi et al. first reported a case of surgically resected IPNB potentially originating from PBGs, according to histological findings. This lesion contained an in situ carcinoma at the bottom of the PBGs [85]. They also reported another case of IPNB potentially originating from PBGs and found that the neoplastic epithelia of the tumor expressed MUC6 gastric mucin, which was strongly expressed in PBGs, but not in the epithelia lining bile duct [86], further supporting the possibility of PBGs as the cellular origin of IPNB. Strong expression of MUC6 in IPNB was confirmed by other studies that reported cases of possible PBG-derived IPNBs [87,88]. In the case of IPNB reported by Miyata et al. the cystic tumor did not communicate with the bile duct lumen but lacked features of MCNs, suggesting that communication with the bile duct lumen might be lost during development and progression of IPNB from PBGs [87]. Thus, IPNBs may arise, at least in part, from PBGs. According to the classification of IPMNs, which are classified into the main duct type and branch type, IPNBs arising from PBGs may correspond to the branch type IPMN [85]. Furthermore, IPNBs originating from PBGs have been suggested as preneoplastic lesions of mucin-producing CCAs, which morphologically resemble PBGs [89].

9. Future Perspectives

As discussed in this review, increasing focus is being placed on PBGs. Because biliary atresia is a leading cause of pediatric liver transplantation [90], and ischemic stricture of the bile duct is one of the most common complications following liver transplantation [91], understanding the mechanisms responsible for bile duct regeneration will be important for the identification of new therapeutic strategies for these conditions. We recently established an organoid culture system from mouse EHBD, as mentioned above [12], and more recently, bioengineered bile duct-like tubes generated using human EHBD-derived organoids were transplanted into the mouse injured bile duct to repair it [92]. This study is promising in terms of regenerative medicine for biliary diseases and has potential clinical applications. However, cellular and molecular understanding of the endogenenous regenerative mechanism of the bile duct has the same importance as generating a more effective problem solving strategy. In this sense, clarifying whether and how PBGs are implicated in homeostasis and regeneration of the bile duct is mandatory. In addition, recent histopathological and experimental studies have suggested that some chronic inflammation-driven CCAs and IPNBs are likely to originate from PBGs. CCA is one of the most challenging malignancies with poor overall survival; thus, identification of the cellular origin is crucial in enhancing our understanding of the mechanisms regulating the process of cholangiocarcinogenesis. How could the knowledge and insights of PBGs as the cellular origin of biliary tract cancer be transferred for the clinic-pathological evaluation of CCA? For example, to diagnose a malignant biliary structure due to CCA, brushing cytology and intraductal biopsies are usually performed during endoscopic retrograde cholangiography, but their sensitivities are relatively low (approximately 50%) [93]. Such low sensitivities may be attributable to the fact that CCAs originating from PBGs do not appear at the luminal surface, but spread subepithelially as seen in KTC-K19CreERT mice. In addition, CCAs with periductal infiltration are known to have a poor prognosis with higher rates of recurrence following resection [94]. Therefore, CCAs originating from PBGs may be associated with a worse clinical outcome due to delayed diagnosis and periductal progression. However, although we introduced recent evidence suggesting the possibility of PBGs as a stem/progenitor cell niche of BECs, and suggested the cellular origins of CCA, there is no conclusive evidence at present. To definitively determine these origins, experiments of cell fate mapping for PBGs using PBG specific gene recombination are needed. Because a specific marker of PBGs has not been identified, this remains a subject of future investigation. Furthermore, niches for stem/progenitor cells and tumor-originating cells are generally supported by microenviroments that regulate their stemness by providing cues in the form of cell–cell contacts and/or secreted factors [95]. However, it remains almost completely unknown how such a microenvironment is maintained in PBGs. Therefore, research of PBGs has only begun, and further studies are needed.

Author Contributions

H.N. wrote the paper and prepared figures and tables; Y.H., T.Y., S.K., N.S. revised manuscript and prepared figures and tables; K.K. supervised the entire project.

Acknowledgments

This study was supported by JSPS KAKENHI Grant number 18H02789, Uehara Memorial Foundation, Daiichi Sankyo Foundation of Life Science, and Bristol–Myers Squibb Research Grant.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Rizvi, S.; Gores, G.J. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 2013, 145, 1215–1229. [Google Scholar] [CrossRef] [PubMed]
  2. Rizvi, S.; Khan, S.A.; Hallemeier, C.L.; Kelley, R.K.; Gores, G.J. Cholangiocarcinoma—Evolving concepts and therapeutic strategies. Nat. Rev. Clin. Oncol. 2018, 15, 95–111. [Google Scholar] [CrossRef] [PubMed]
  3. Nakanuma, Y.; Miyata, T.; Uchida, T. Latest advances in the pathological understanding of cholangiocarcinomas. Expert Rev. Gastroenterol. Hepatol. 2016, 10, 113–127. [Google Scholar] [CrossRef] [PubMed]
  4. Rizvi, S.; Gores, G.J. Emerging molecular therapeutic targets for cholangiocarcinoma. J. Hepatol. 2017, 67, 632–644. [Google Scholar] [CrossRef] [PubMed]
  5. Moeini, A.; Sia, D.; Bardeesy, N.; Mazzaferro, V.; Llovet, J.M. Molecular pathogenesis and targeted therapies for intrahepatic cholangiocarcinoma. Clin. Cancer Res. 2016, 22, 291–300. [Google Scholar] [CrossRef] [PubMed]
  6. Rycaj, K.; Tang, D.G. Cell-of-origin of cancer versus cancer stem cells: Assays and interpretations. Cancer Res. 2015, 75, 4003–4011. [Google Scholar] [CrossRef] [PubMed]
  7. Hayakawa, Y.; Fox, J.G.; Wang, T.C. The origins of gastric cancer from gastric stem cells: Lessons from mouse models. Cell. Mol. Gastroenterol. Hepatol. 2017, 3, 331–338. [Google Scholar] [CrossRef] [PubMed]
  8. Barker, N.; Ridgway, R.A.; van Es, J.H.; van de Wetering, M.; Begthel, H.; van den Born, M.; Danenberg, E.; Clarke, A.R.; Sansom, O.J.; Clevers, H. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009, 457, 608–611. [Google Scholar] [CrossRef] [PubMed]
  9. Sekiya, S.; Suzuki, A. Intrahepatic cholangiocarcinoma can arise from notch-mediated conversion of hepatocytes. J. Clin. Investig. 2012, 122, 3914–3918. [Google Scholar] [CrossRef] [PubMed]
  10. Fan, B.; Malato, Y.; Calvisi, D.F.; Naqvi, S.; Razumilava, N.; Ribback, S.; Gores, G.J.; Dombrowski, F.; Evert, M.; Chen, X.; et al. Cholangiocarcinomas can originate from hepatocytes in mice. J. Clin. Investig. 2012, 122, 2911–2915. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  11. Lanzoni, G.; Cardinale, V.; Carpino, G. The hepatic, biliary, and pancreatic network of stem/progenitor cell niches in humans: A new reference frame for disease and regeneration. Hepatology 2016, 64, 277–286. [Google Scholar] [CrossRef] [PubMed]
  12. Nakagawa, H.; Suzuki, N.; Hirata, Y.; Hikiba, Y.; Hayakawa, Y.; Kinoshita, H.; Ihara, S.; Uchino, K.; Nishikawa, Y.; Ijichi, H.; et al. Biliary epithelial injury-induced regenerative response by IL-33 promotes cholangiocarcinogenesis from peribiliary glands. Proc. Natl. Acad. Sci. USA 2017, 114, E3806–E3815. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Banales, J.M.; Cardinale, V.; Carpino, G.; Marzioni, M.; Andersen, J.B.; Invernizzi, P.; Lind, G.E.; Folseraas, T.; Forbes, S.J.; Fouassier, L.; et al. Expert consensus document: Cholangiocarcinoma: Current knowledge and future perspectives consensus statement from the european network for the study of cholangiocarcinoma (ENS-CCA). Nat. Rev. Gastroenterol. Hepatol. 2016, 13, 261–280. [Google Scholar] [CrossRef] [PubMed]
  14. Shin, H.R.; Oh, J.K.; Masuyer, E.; Curado, M.P.; Bouvard, V.; Fang, Y.Y.; Wiangnon, S.; Sripa, B.; Hong, S.T. Epidemiology of cholangiocarcinoma: An update focusing on risk factors. Cancer Sci. 2010, 101, 579–585. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Bergquist, A.; Ekbom, A.; Olsson, R.; Kornfeldt, D.; Loof, L.; Danielsson, A.; Hultcrantz, R.; Lindgren, S.; Prytz, H.; Sandberg-Gertzen, H.; et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J. Hepatol. 2002, 36, 321–327. [Google Scholar] [CrossRef]
  16. Burak, K.; Angulo, P.; Pasha, T.M.; Egan, K.; Petz, J.; Lindor, K.D. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am. J. Gastroenterol. 2004, 99, 523–526. [Google Scholar] [CrossRef] [PubMed]
  17. Morris-Stiff, G.; Bhati, C.; Olliff, S.; Hubscher, S.; Gunson, B.; Mayer, D.; Mirza, D.; Buckels, J.; Bramhall, S.R. Cholangiocarcinoma complicating primary sclerosing cholangitis: A 24-year experience. Dig. Surg. 2008, 25, 126–132. [Google Scholar] [CrossRef] [PubMed]
  18. Bergquist, A.; von Seth, E. Epidemiology of cholangiocarcinoma. Best Pract. Res. Clin. Gastroenterol. 2015, 29, 221–232. [Google Scholar] [CrossRef] [PubMed]
  19. Balkwill, F.; Mantovani, A. Inflammation and cancer: Back to virchow? Lancet 2001, 357, 539–545. [Google Scholar] [CrossRef]
  20. Nakagawa, H.; Maeda, S. Inflammation- and stress-related signaling pathways in hepatocarcinogenesis. World J. Gastroenterol. 2012, 18, 4071–4081. [Google Scholar] [CrossRef] [PubMed]
  21. Maeda, S.; Kamata, H.; Luo, J.L.; Leffert, H.; Karin, M. Ikkbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005, 121, 977–990. [Google Scholar] [CrossRef] [PubMed]
  22. Naugler, W.E.; Sakurai, T.; Kim, S.; Maeda, S.; Kim, K.; Elsharkawy, A.M.; Karin, M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007, 317, 121–124. [Google Scholar] [CrossRef] [PubMed]
  23. Nakagawa, H.; Umemura, A.; Taniguchi, K.; Font-Burgada, J.; Dhar, D.; Ogata, H.; Zhong, Z.; Valasek, M.A.; Seki, E.; Hidalgo, J.; et al. ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. Cancer Cell 2014, 26, 331–343. [Google Scholar] [CrossRef] [PubMed]
  24. Nakamura, H.; Arai, Y.; Totoki, Y.; Shirota, T.; Elzawahry, A.; Kato, M.; Hama, N.; Hosoda, F.; Urushidate, T.; Ohashi, S.; et al. Genomic spectra of biliary tract cancer. Nat. Genet. 2015, 47, 1003–1010. [Google Scholar] [CrossRef] [PubMed]
  25. Shibata, T.; Arai, Y.; Totoki, Y. Molecular genomic landscapes of hepatobiliary cancer. Cancer Sci. 2018, 109, 1282–1291. [Google Scholar] [CrossRef] [PubMed]
  26. Jusakul, A.; Cutcutache, I.; Yong, C.H.; Lim, J.Q.; Huang, M.N.; Padmanabhan, N.; Nellore, V.; Kongpetch, S.; Ng, A.W.T.; Ng, L.M.; et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 2017, 7, 1116–1135. [Google Scholar] [CrossRef] [PubMed]
  27. Chan-On, W.; Nairismagi, M.L.; Ong, C.K.; Lim, W.K.; Dima, S.; Pairojkul, C.; Lim, K.H.; McPherson, J.R.; Cutcutache, I.; Heng, H.L.; et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat. Genet. 2013, 45, 1474–1478. [Google Scholar] [CrossRef] [PubMed]
  28. Zou, S.; Li, J.; Zhou, H.; Frech, C.; Jiang, X.; Chu, J.S.; Zhao, X.; Li, Y.; Li, Q.; Wang, H.; et al. Mutational landscape of intrahepatic cholangiocarcinoma. Nat. Commun. 2014, 5, 5696. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  29. Fujimoto, A.; Furuta, M.; Shiraishi, Y.; Gotoh, K.; Kawakami, Y.; Arihiro, K.; Nakamura, T.; Ueno, M.; Ariizumi, S.; Nguyen, H.H.; et al. Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity. Nat. Commun. 2015, 6, 6120. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  30. Javle, M.; Lowery, M.; Shroff, R.T.; Weiss, K.H.; Springfeld, C.; Borad, M.J.; Ramanathan, R.K.; Goyal, L.; Sadeghi, S.; Macarulla, T.; et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J. Clin. Oncol. 2018, 36, 276–282. [Google Scholar] [CrossRef] [PubMed]
  31. De Jong, I.E.M.; van Leeuwen, O.B.; Lisman, T.; Gouw, A.S.H.; Porte, R.J. Repopulating the biliary tree from the peribiliary glands. Biochim. Biophys. Acta 2018, 1864, 1524–1531. [Google Scholar] [CrossRef] [PubMed]
  32. Roskams, T.; Desmet, V. Embryology of extra- and intrahepatic bile ducts, the ductal plate. Anat. Rec. 2008, 291, 628–635. [Google Scholar] [CrossRef] [PubMed]
  33. Rao, R.K.; Samak, G. Bile duct epithelial tight junctions and barrier function. Tissue Barriers 2013, 1, e25718. [Google Scholar] [CrossRef] [PubMed]
  34. De Assuncao, T.M.; Jalan-Sakrikar, N.; Huebert, R.C. Regenerative medicine and the biliary tree. Semin. Liver Dis. 2017, 37, 17–27. [Google Scholar] [CrossRef] [PubMed]
  35. Kordes, C.; Haussinger, D. Hepatic stem cell niches. J. Clin. Investig. 2013, 123, 1874–1880. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Blanpain, C. Tracing the cellular origin of cancer. Nat. Cell Biol. 2013, 15, 126–134. [Google Scholar] [CrossRef] [PubMed]
  37. Yanger, K.; Zong, Y.; Maggs, L.R.; Shapira, S.N.; Maddipati, R.; Aiello, N.M.; Thung, S.N.; Wells, R.G.; Greenbaum, L.E.; Stanger, B.Z. Robust cellular reprogramming occurs spontaneously during liver regeneration. Genes Dev. 2013, 27, 719–724. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  38. Tarlow, B.D.; Pelz, C.; Naugler, W.E.; Wakefield, L.; Wilson, E.M.; Finegold, M.J.; Grompe, M. Bipotential adult liver progenitors are derived from chronically injured mature hepatocytes. Cell Stem Cell 2014, 15, 605–618. [Google Scholar] [CrossRef] [PubMed]
  39. Tanimizu, N.; Nishikawa, Y.; Ichinohe, N.; Akiyama, H.; Mitaka, T. Sry HMG box protein 9-positive (Sox9+) epithelial cell adhesion molecule-negative (EpCAM-) biphenotypic cells derived from hepatocytes are involved in mouse liver regeneration. J. Biol. Chem. 2014, 289, 7589–7598. [Google Scholar] [CrossRef] [PubMed]
  40. Aishima, S.; Fujita, N.; Mano, Y.; Iguchi, T.; Taketomi, A.; Maehara, Y.; Oda, Y.; Tsuneyoshi, M. P62+ hyaline inclusions in intrahepatic cholangiocarcinoma associated with viral hepatitis or alcoholic liver disease. Am. J. Clin. Pathol. 2010, 134, 457–465. [Google Scholar] [CrossRef] [PubMed]
  41. Ikenoue, T.; Terakado, Y.; Nakagawa, H.; Hikiba, Y.; Fujii, T.; Matsubara, D.; Noguchi, R.; Zhu, C.; Yamamoto, K.; Kudo, Y.; et al. A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion. Sci. Rep. 2016, 6, 23899. [Google Scholar] [CrossRef] [PubMed]
  42. Guest, R.V.; Boulter, L.; Kendall, T.J.; Minnis-Lyons, S.E.; Walker, R.; Wigmore, S.J.; Sansom, O.J.; Forbes, S.J. Cell lineage tracing reveals a biliary origin of intrahepatic cholangiocarcinoma. Cancer Res. 2014, 74, 1005–1010. [Google Scholar] [CrossRef] [PubMed]
  43. Spence, J.R.; Lange, A.W.; Lin, S.C.; Kaestner, K.H.; Lowy, A.M.; Kim, I.; Whitsett, J.A.; Wells, J.M. Sox17 regulates organ lineage segregation of ventral foregut progenitor cells. Dev. Cell 2009, 17, 62–74. [Google Scholar] [CrossRef] [PubMed]
  44. Hale, M.A.; Kagami, H.; Shi, L.; Holland, A.M.; Elsasser, H.P.; Hammer, R.E.; MacDonald, R.J. The homeodomain protein PDX1 is required at mid-pancreatic development for the formation of the exocrine pancreas. Dev. Biol. 2005, 286, 225–237. [Google Scholar] [CrossRef] [PubMed]
  45. Antoniou, A.; Raynaud, P.; Cordi, S.; Zong, Y.; Tronche, F.; Stanger, B.Z.; Jacquemin, P.; Pierreux, C.E.; Clotman, F.; Lemaigre, F.P. Intrahepatic bile ducts develop according to a new mode of tubulogenesis regulated by the transcription factor SOX9. Gastroenterology 2009, 136, 2325–2333. [Google Scholar] [CrossRef] [PubMed]
  46. Cardinale, V.; Carpino, G.; Reid, L.; Gaudio, E.; Alvaro, D. Multiple cells of origin in cholangiocarcinoma underlie biological, epidemiological and clinical heterogeneity. World J. Gastrointest. Oncol. 2012, 4, 94–102. [Google Scholar] [CrossRef] [PubMed]
  47. Carpino, G.; Cardinale, V.; Onori, P.; Franchitto, A.; Berloco, P.B.; Rossi, M.; Wang, Y.; Semeraro, R.; Anceschi, M.; Brunelli, R.; et al. Biliary tree stem/progenitor cells in glands of extrahepatic and intraheptic bile ducts: An anatomical in situ study yielding evidence of maturational lineages. J. Anat. 2012, 220, 186–199. [Google Scholar] [CrossRef] [PubMed]
  48. Cardinale, V.; Wang, Y.; Carpino, G.; Cui, C.B.; Gatto, M.; Rossi, M.; Berloco, P.B.; Cantafora, A.; Wauthier, E.; Furth, M.E.; et al. Multipotent stem/progenitor cells in human biliary tree give rise to hepatocytes, cholangiocytes, and pancreatic islets. Hepatology 2011, 54, 2159–2172. [Google Scholar] [CrossRef] [PubMed]
  49. Dipaola, F.; Shivakumar, P.; Pfister, J.; Walters, S.; Sabla, G.; Bezerra, J.A. Identification of intramural epithelial networks linked to peribiliary glands that express progenitor cell markers and proliferate after injury in mice. Hepatology 2013, 58, 1486–1496. [Google Scholar] [CrossRef] [PubMed]
  50. Sutton, M.E.; op den Dries, S.; Koster, M.H.; Lisman, T.; Gouw, A.S.; Porte, R.J. Regeneration of human extrahepatic biliary epithelium: The peribiliary glands as progenitor cell compartment. Liver Int. 2012, 32, 554–559. [Google Scholar] [CrossRef] [PubMed]
  51. Carpino, G.; Cardinale, V.; Renzi, A.; Hov, J.R.; Berloco, P.B.; Rossi, M.; Karlsen, T.H.; Alvaro, D.; Gaudio, E. Activation of biliary tree stem cells within peribiliary glands in primary sclerosing cholangitis. J. Hepatol. 2015, 63, 1220–1228. [Google Scholar] [CrossRef] [PubMed]
  52. Hughes, N.R.; Pairojkul, C.; Royce, S.G.; Clouston, A.; Bhathal, P.S. Liver fluke-associated and sporadic cholangiocarcinoma: An immunohistochemical study of bile duct, peribiliary gland and tumour cell phenotypes. J. Clin. Pathol. 2006, 59, 1073–1078. [Google Scholar] [CrossRef] [PubMed]
  53. Terada, T.; Nakanuma, Y. Pathologic observations of intrahepatic peribiliary glands in 1000 consecutive autopsy livers: IV. Hyperplasia of intramural and extramural glands. Hum. Pathol. 1992, 23, 483–490. [Google Scholar] [CrossRef]
  54. Op den Dries, S.; Westerkamp, A.C.; Karimian, N.; Gouw, A.S.; Bruinsma, B.G.; Markmann, J.F.; Lisman, T.; Yeh, H.; Uygun, K.; Martins, P.N.; et al. Injury to peribiliary glands and vascular plexus before liver transplantation predicts formation of non-anastomotic biliary strictures. J. Hepatol. 2014, 60, 1172–1179. [Google Scholar] [CrossRef] [PubMed]
  55. Carpino, G.; Puca, R.; Cardinale, V.; Renzi, A.; Scafetta, G.; Nevi, L.; Rossi, M.; Berloco, P.B.; Ginanni Corradini, S.; Reid, L.M.; et al. Peribiliary glands as a niche of extrapancreatic precursors yielding insulin-producing cells in experimental and human diabetes. Stem Cells 2016, 34, 1332–1342. [Google Scholar] [CrossRef] [PubMed]
  56. Berx, G.; van Roy, F. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb. Perspect. Biol. 2009, 1, a003129. [Google Scholar] [CrossRef] [PubMed]
  57. Nitta, T.; Mitsuhashi, T.; Hatanaka, Y.; Miyamoto, M.; Oba, K.; Tsuchikawa, T.; Suzuki, Y.; Hatanaka, K.C.; Hirano, S.; Matsuno, Y. Prognostic significance of epithelial-mesenchymal transition-related markers in extrahepatic cholangiocarcinoma: Comprehensive immunohistochemical study using a tissue microarray. Br. J. Cancer 2014, 111, 1363–1372. [Google Scholar] [CrossRef] [PubMed]
  58. Nakagawa, H.; Hikiba, Y.; Hirata, Y.; Font-Burgada, J.; Sakamoto, K.; Hayakawa, Y.; Taniguchi, K.; Umemura, A.; Kinoshita, H.; Sakitani, K.; et al. Loss of liver E-cadherin induces sclerosing cholangitis and promotes carcinogenesis. Proc. Natl. Acad. Sci. USA 2014, 111, 1090–1095. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  59. Yeh, T.H.; Krauland, L.; Singh, V.; Zou, B.; Devaraj, P.; Stolz, D.B.; Franks, J.; Monga, S.P.; Sasatomi, E.; Behari, J. Liver-specific beta-catenin knockout mice have bile canalicular abnormalities, bile secretory defect, and intrahepatic cholestasis. Hepatology 2010, 52, 1410–1419. [Google Scholar] [CrossRef] [PubMed]
  60. Herr, K.J.; Tsang, Y.H.; Ong, J.W.; Li, Q.; Yap, L.L.; Yu, W.; Yin, H.; Bogorad, R.L.; Dahlman, J.E.; Chan, Y.G.; et al. Loss of alpha-catenin elicits a cholestatic response and impairs liver regeneration. Sci. Rep. 2014, 4, 6835. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  61. Van Hengel, J.; Van den Broeke, C.; Pieters, T.; Libbrecht, L.; Hofmann, I.; van Roy, F. Inactivation of p120 catenin in mice disturbs intrahepatic bile duct development and aggravates liver carcinogenesis. Eur. J. Cell Biol. 2016, 95, 574–584. [Google Scholar] [CrossRef] [PubMed]
  62. Rygiel, K.A.; Robertson, H.; Marshall, H.L.; Pekalski, M.; Zhao, L.; Booth, T.A.; Jones, D.E.; Burt, A.D.; Kirby, J.A. Epithelial-mesenchymal transition contributes to portal tract fibrogenesis during human chronic liver disease. Lab. Investig. 2008, 88, 112–123. [Google Scholar] [CrossRef] [PubMed]
  63. Pollheimer, M.J.; Racedo, S.; Mikels-Vigdal, A.; Marshall, D.; Bowlus, C.; Lackner, C.; Madl, T.; Karlsen, T.H.; Hov, J.R.; Lyman, S.K.; et al. Lysyl oxidase-like protein 2 (LOXL2) modules barrier function in cholangiocytes in cholestasis. J. Hepatol. 2018, in press. [Google Scholar] [CrossRef] [PubMed]
  64. Terada, T.; Nakanuma, Y. Pathological observations of intrahepatic peribiliary glands in 1000 consecutive autopsy livers. II. A possible source of cholangiocarcinoma. Hepatology 1990, 12, 92–97. [Google Scholar] [CrossRef] [PubMed]
  65. Hsu, M.; Sasaki, M.; Igarashi, S.; Sato, Y.; Nakanuma, Y. KRAS and GNAS mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas. Cancer 2013, 119, 1669–1674. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  66. Razumilava, N.; Gradilone, S.A.; Smoot, R.L.; Mertens, J.C.; Bronk, S.F.; Sirica, A.E.; Gores, G.J. Non-canonical hedgehog signaling contributes to chemotaxis in cholangiocarcinoma. J. Hepatol. 2014, 60, 599–605. [Google Scholar] [CrossRef] [PubMed]
  67. Sato, H.; Nakanuma, Y.; Kozaka, K.; Sato, Y.; Ikeda, H. Spread of hilar cholangiocarcinomas via peribiliary gland network: A hither-to-unrecognized route of periductal infiltration. Int. J. Clin. Exp. Pathol. 2013, 6, 318–322. [Google Scholar] [PubMed]
  68. Grivennikov, S.I.; Greten, F.R.; Karin, M. Immunity, inflammation, and cancer. Cell 2010, 140, 883–899. [Google Scholar] [CrossRef] [PubMed]
  69. Molofsky, A.B.; Savage, A.K.; Locksley, R.M. Interleukin-33 in tissue homeostasis, injury, and inflammation. Immunity 2015, 42, 1005–1019. [Google Scholar] [CrossRef] [PubMed]
  70. Li, J.; Razumilava, N.; Gores, G.J.; Walters, S.; Mizuochi, T.; Mourya, R.; Bessho, K.; Wang, Y.H.; Glaser, S.S.; Shivakumar, P.; et al. Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J. Clin. Investig. 2014, 124, 3241–3251. [Google Scholar] [CrossRef] [PubMed]
  71. Islam, S.A.; Luster, A.D. T cell homing to epithelial barriers in allergic disease. Nat. Med. 2012, 18, 705–715. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  72. Yu, Q.; Li, X.Y.; Cheng, X.D.; Shen, L.P.; Fang, F.; Zhang, B.; Hua, H.; Yan, C.; Tang, R.X.; Zheng, K.Y. Expression and potential roles of IL-33/ST2 in the immune regulation during clonorchis sinensis infection. Parasitol. Res. 2016, 115, 2299–2305. [Google Scholar] [CrossRef] [PubMed]
  73. Sawada, R.; Ku, Y.; Akita, M.; Otani, K.; Fujikura, K.; Itoh, T.; Ajiki, T.; Fukumoto, T.; Kakeji, Y.; Zen, Y. IL-33 overexpression reflects less aggressive tumour features in large-duct type cholangiocarcinomas. Histopathology 2018. [Google Scholar] [CrossRef] [PubMed]
  74. Yamada, D.; Rizvi, S.; Razumilava, N.; Bronk, S.F.; Davila, J.I.; Champion, M.D.; Borad, M.J.; Bezerra, J.A.; Chen, X.; Gores, G.J. IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism. Hepatology 2015, 61, 1627–1642. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  75. He, G.; Dhar, D.; Nakagawa, H.; Font-Burgada, J.; Ogata, H.; Jiang, Y.; Shalapour, S.; Seki, E.; Yost, S.E.; Jepsen, K.; et al. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell 2013, 155, 384–396. [Google Scholar] [CrossRef] [PubMed]
  76. Nakagawa, H.; Maeda, S.; Yoshida, H.; Tateishi, R.; Masuzaki, R.; Ohki, T.; Hayakawa, Y.; Kinoshita, H.; Yamakado, M.; Kato, N.; et al. Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis c patients: An analysis based on gender differences. Int. J. Cancer 2009, 125, 2264–2269. [Google Scholar] [CrossRef] [PubMed]
  77. Grivennikov, S.; Karin, E.; Terzic, J.; Mucida, D.; Yu, G.Y.; Vallabhapurapu, S.; Scheller, J.; Rose-John, S.; Cheroutre, H.; Eckmann, L.; et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15, 103–113. [Google Scholar] [CrossRef] [PubMed]
  78. Sia, D.; Hoshida, Y.; Villanueva, A.; Roayaie, S.; Ferrer, J.; Tabak, B.; Peix, J.; Sole, M.; Tovar, V.; Alsinet, C.; et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 2013, 144, 829–840. [Google Scholar] [CrossRef] [PubMed]
  79. Goydos, J.S.; Brumfield, A.M.; Frezza, E.; Booth, A.; Lotze, M.T.; Carty, S.E. Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: Validation of utility as a clinical marker. Ann. Surg. 1998, 227, 398–404. [Google Scholar] [CrossRef] [PubMed]
  80. Cheon, Y.K.; Cho, Y.D.; Moon, J.H.; Jang, J.Y.; Kim, Y.S.; Kim, Y.S.; Lee, M.S.; Lee, J.S.; Shim, C.S. Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy. Am. J. Gastroenterol. 2007, 102, 2164–2170. [Google Scholar] [CrossRef] [PubMed]
  81. Hernandez, C.; Huebener, P.; Pradere, J.P.; Antoine, D.J.; Friedman, R.A.; Schwabe, R.F. HMGB1 links chronic liver injury to progenitor responses and hepatocarcinogenesis. J. Clin. Investig. 2018. [Google Scholar] [CrossRef] [PubMed]
  82. Khambu, B.; Huda, N.; Chen, X.; Antoine, D.J.; Li, Y.; Dai, G.; Kohler, U.A.; Zong, W.X.; Waguri, S.; Werner, S.; et al. HMGB1 promotes ductular reaction and tumorigenesis in autophagy-deficient livers. J. Clin. Investig. 2018, 128. [Google Scholar] [CrossRef] [PubMed]
  83. Rocha, F.G.; Lee, H.; Katabi, N.; DeMatteo, R.P.; Fong, Y.; D’Angelica, M.I.; Allen, P.J.; Klimstra, D.S.; Jarnagin, W.R. Intraductal papillary neoplasm of the bile duct: A biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas? Hepatology 2012, 56, 1352–1360. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  84. Zen, Y.; Fujii, T.; Itatsu, K.; Nakamura, K.; Minato, H.; Kasashima, S.; Kurumaya, H.; Katayanagi, K.; Kawashima, A.; Masuda, S.; et al. Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas. Hepatology 2006, 44, 1333–1343. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  85. Nakanishi, Y.; Zen, Y.; Hirano, S.; Tanaka, E.; Takahashi, O.; Yonemori, A.; Doumen, H.; Kawakami, H.; Itoh, T.; Nakanuma, Y.; et al. Intraductal oncocytic papillary neoplasm of the bile duct: The first case of peribiliary gland origin. J. Hepato Biliary Pancreat. Surg. 2009, 16, 869–873. [Google Scholar] [CrossRef] [PubMed]
  86. Nakanishi, Y.; Nakanuma, Y.; Ohara, M.; Iwao, T.; Kimura, N.; Ishidate, T.; Kijima, H. Intraductal papillary neoplasm arising from peribiliary glands connecting with the inferior branch of the bile duct of the anterior segment of the liver. Pathol. Int. 2011, 61, 773–777. [Google Scholar] [CrossRef] [PubMed]
  87. Miyata, T.; Uesaka, K.; Nakanuma, Y. Cystic and papillary neoplasm at the hepatic hilum possibly originating in the peribiliary glands. Case Rep. Pathol. 2016, 2016, 9130754. [Google Scholar] [CrossRef] [PubMed]
  88. Uchida, T.; Yamamoto, Y.; Ito, T.; Okamura, Y.; Sugiura, T.; Uesaka, K.; Nakanuma, Y. Cystic micropapillary neoplasm of peribiliary glands with concomitant perihilar cholangiocarcinoma. World J. Gastroenterol. 2016, 22, 2391–2397. [Google Scholar] [CrossRef] [PubMed]
  89. Cardinale, V.; Wang, Y.; Carpino, G.; Reid, L.M.; Gaudio, E.; Alvaro, D. Mucin-producing cholangiocarcinoma might derive from biliary tree stem/progenitor cells located in peribiliary glands. Hepatology 2012, 55, 2041–2042. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  90. Murray, K.F.; Carithers, R.L., Jr. Aasld practice guidelines: Evaluation of the patient for liver transplantation. Hepatology 2005, 41, 1407–1432. [Google Scholar] [CrossRef] [PubMed]
  91. Skaro, A.I.; Jay, C.L.; Baker, T.B.; Wang, E.; Pasricha, S.; Lyuksemburg, V.; Martin, J.A.; Feinglass, J.M.; Preczewski, L.B.; Abecassis, M.M. The impact of ischemic cholangiopathy in liver transplantation using donors after cardiac death: The untold story. Surgery 2009, 146, 543–553. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  92. Sampaziotis, F.; Justin, A.W.; Tysoe, O.C.; Sawiak, S.; Godfrey, E.M.; Upponi, S.S.; Gieseck, R.L., III; de Brito, M.C.; Berntsen, N.L.; Gomez-Vazquez, M.J.; et al. Reconstruction of the mouse extrahepatic biliary tree using primary human extrahepatic cholangiocyte organoids. Nat. Med. 2017, 23, 954–963. [Google Scholar] [CrossRef] [PubMed]
  93. Navaneethan, U.; Njei, B.; Lourdusamy, V.; Konjeti, R.; Vargo, J.J.; Parsi, M.A. Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures: A systematic review and meta-analysis. Gastrointest. Endosc. 2015, 81, 168–176. [Google Scholar] [CrossRef] [PubMed]
  94. Blechacz, B.; Komuta, M.; Roskams, T.; Gores, G.J. Clinical diagnosis and staging of cholangiocarcinoma. Nat. Rev. Gastroenterol. Hepatol. 2011, 8, 512–522. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  95. Plaks, V.; Kong, N.; Werb, Z. The cancer stem cell niche: How essential is the niche in regulating stemness of tumor cells? Cell Stem Cell 2015, 16, 225–238. [Google Scholar] [CrossRef] [PubMed]
Ijms 19 01745 g001 550
Figure 1. Histological findings of extrahepatic bile ducts (EHBDs) in KTC-K19CreERT mice. (A) Hematoxylin and eosin (H&E)-stained images of EHBDs from KTC-K19CreERT mice at the indicated time points following tamoxifen (TAM) administration (scale bar: lower right panel, 100 μm; others, 50 μm). KTC-K19CreERT mice were orally administered 200 mg/kg TAM for three consecutive days and sacrificed at the indicated time points. Black arrowheads, normal peribiliary glands (PBGs); blue arrowheads, biliary epithelial cells (BECs) detaching from the bile duct epithelium; yellow arrowheads, enlarged and dysplastic PBGs; (B) Ki67 immunostaining of EHBDs from Cre-negative control and KTC-K19CreERT mice at 10 days following TAM administration (scale bar, 50 μm); (C) LacZ-stained images of EHBDs of KTC-LacZ-K19CreERT mice at the indicated time points following TAM administration (scale bar, 200 μm). LacZ expression was detected by staining with X-gal, as described previously [12]. LacZ-positive BECs were detached from the bile duct epithelium, and subsequently luminal surface BECs were replaced by LacZ-negative cells. However, LacZ-positive cells remained in the PBGs, and eventually LacZ-positive cancer glands spread through the subepithelial area; (D) H&E-stained images of EHBD organoids from Cre-negative KTC mice infected with Cre-expressing or control lentivirus (scale bar: 50 μm). To induce recombination, organoids were infected with Cre-expressing or control lentivirus, and transduced cells were selected using puromycin, as described previously [12].
Figure 1. Histological findings of extrahepatic bile ducts (EHBDs) in KTC-K19CreERT mice. (A) Hematoxylin and eosin (H&E)-stained images of EHBDs from KTC-K19CreERT mice at the indicated time points following tamoxifen (TAM) administration (scale bar: lower right panel, 100 μm; others, 50 μm). KTC-K19CreERT mice were orally administered 200 mg/kg TAM for three consecutive days and sacrificed at the indicated time points. Black arrowheads, normal peribiliary glands (PBGs); blue arrowheads, biliary epithelial cells (BECs) detaching from the bile duct epithelium; yellow arrowheads, enlarged and dysplastic PBGs; (B) Ki67 immunostaining of EHBDs from Cre-negative control and KTC-K19CreERT mice at 10 days following TAM administration (scale bar, 50 μm); (C) LacZ-stained images of EHBDs of KTC-LacZ-K19CreERT mice at the indicated time points following TAM administration (scale bar, 200 μm). LacZ expression was detected by staining with X-gal, as described previously [12]. LacZ-positive BECs were detached from the bile duct epithelium, and subsequently luminal surface BECs were replaced by LacZ-negative cells. However, LacZ-positive cells remained in the PBGs, and eventually LacZ-positive cancer glands spread through the subepithelial area; (D) H&E-stained images of EHBD organoids from Cre-negative KTC mice infected with Cre-expressing or control lentivirus (scale bar: 50 μm). To induce recombination, organoids were infected with Cre-expressing or control lentivirus, and transduced cells were selected using puromycin, as described previously [12].
Ijms 19 01745 g001
Ijms 19 01745 g002 550
Figure 2. Proposed mechanisms involving the BEC injury-induced regenerative inflammatory response and cholangiocarcinogenesis. Dying or damaged luminal surface BECs release interleukin (IL)-33 and other alarmins to induce regenerative responses by PBGs. IL-33 promotes proliferation of PBGs, directly or indirectly, through activation of autocrine IL-6 signaling or ILC2, which produces effector cytokines and growth factors, such as IL-13 and amphiregulin (AREG). However, cells harboring mutations survived in the PBGs; therefore, the regenerative response to biliary injury resulted in development of cholangiocarcinoma (CCA) from PBGs. During this process, a microenvironment in the PBGs supports cancer-initiating cells in the form of cell–cell contacts and/or secreted factors such as Sonic Hedgehog (Shh) released from surrounding fibroblasts, although the precise mechanisms remain poorly understood. EMT—epithelial–mesenchymal transition.
Figure 2. Proposed mechanisms involving the BEC injury-induced regenerative inflammatory response and cholangiocarcinogenesis. Dying or damaged luminal surface BECs release interleukin (IL)-33 and other alarmins to induce regenerative responses by PBGs. IL-33 promotes proliferation of PBGs, directly or indirectly, through activation of autocrine IL-6 signaling or ILC2, which produces effector cytokines and growth factors, such as IL-13 and amphiregulin (AREG). However, cells harboring mutations survived in the PBGs; therefore, the regenerative response to biliary injury resulted in development of cholangiocarcinoma (CCA) from PBGs. During this process, a microenvironment in the PBGs supports cancer-initiating cells in the form of cell–cell contacts and/or secreted factors such as Sonic Hedgehog (Shh) released from surrounding fibroblasts, although the precise mechanisms remain poorly understood. EMT—epithelial–mesenchymal transition.
Ijms 19 01745 g002
Table
Table 1. Mouse models for tracing the cellular origin of cholangiocarcinoma (CCA).
Table 1. Mouse models for tracing the cellular origin of cholangiocarcinoma (CCA).
Types of CCAMethods for CCA InductionMethods for Lineage TracingCellular Origin
Intrahepatic CCAChronic thioacetamide (TAA) administrationRosa26-LSL-LacZ mice crossed with AlbuminCreERT mice or K19CreERT miceHepatocytes
Hepatocyte-specific activation of Akt and Notch pathways by hydrodynamic tail vein injectionInjection of adenoassociated virus serotype 8 vector expressing Cre from transthyretin promoter into Rosa26-LSL-EYFP miceHepatocytes
Duct cell-specific Kras activation and PTEN deletionK19CreERT mice crossed with LSL-KrasG12D mice and Ptenflox/flox miceCholangiocytes
Duct cell-specific p53 deletion in combination with chronic TAA administrationK19CreERT mice crossed with p53flox/flox mice and Rosa26-LSL-EYFP miceCholangiocytes
Extrahepatic CCADuct cell-specific activation of Kras and deletion of TGFβR2 and E-cadherinK19CreERT mice crossed with LSL-KrasG12D, Tgfbr2flox/flox, CDH1flox/flox, and Rosa26-LSL-LacZ micePeribiliary glands (PBGs)
Table
Table 2. Stem/progenitor cell markers expressed in PBGs.
Table 2. Stem/progenitor cell markers expressed in PBGs.
Types of Stem/Progenitor Cell MarkersStem/Progenitor Cell Markers Expressed in PBGs
Pluripotency genesOct4, Nanog
Stem cell surface markersCD133, CXCR4, CD44
Markers of endodermal stem cellsPdx1, Sox9, Sox17, Foxa2
Markers of hepatic stem cellsEpCAM, NCAM
Markers of intestinal stem cellsLgr5

Share and Cite

MDPI and ACS Style

Nakagawa, H.; Hayata, Y.; Yamada, T.; Kawamura, S.; Suzuki, N.; Koike, K. Peribiliary Glands as the Cellular Origin of Biliary Tract Cancer. Int. J. Mol. Sci. 2018, 19, 1745. https://doi.org/10.3390/ijms19061745

AMA Style

Nakagawa H, Hayata Y, Yamada T, Kawamura S, Suzuki N, Koike K. Peribiliary Glands as the Cellular Origin of Biliary Tract Cancer. International Journal of Molecular Sciences. 2018; 19(6):1745. https://doi.org/10.3390/ijms19061745

Chicago/Turabian Style

Nakagawa, Hayato, Yuki Hayata, Tomoharu Yamada, Satoshi Kawamura, Nobumi Suzuki, and Kazuhiko Koike. 2018. "Peribiliary Glands as the Cellular Origin of Biliary Tract Cancer" International Journal of Molecular Sciences 19, no. 6: 1745. https://doi.org/10.3390/ijms19061745

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop